These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. Tumor Heterogeneity in Pancreatic Adenocarcinoma. Cros J; Raffenne J; Couvelard A; Poté N Pathobiology; 2018; 85(1-2):64-71. PubMed ID: 28787741 [TBL] [Abstract][Full Text] [Related]
23. Intratumor heterogeneity: origins, clinical significance and optimal strategies for cancer treatment. Mangano A; Lianos GD; Mangano A; Boni L; Dionigi G Future Oncol; 2015; 11(4):561-4. PubMed ID: 25686113 [No Abstract] [Full Text] [Related]
24. Intratumor heterogeneity in evolutionary models of tumor progression. Durrett R; Foo J; Leder K; Mayberry J; Michor F Genetics; 2011 Jun; 188(2):461-77. PubMed ID: 21406679 [TBL] [Abstract][Full Text] [Related]
25. Epigenetic heterogeneity in cancer. Guo M; Peng Y; Gao A; Du C; Herman JG Biomark Res; 2019; 7():23. PubMed ID: 31695915 [TBL] [Abstract][Full Text] [Related]
26. Oral tumor heterogeneity, its implications for patient monitoring and designing anti-cancer strategies. Mishra R Pathol Res Pract; 2024 Jan; 253():154953. PubMed ID: 38039738 [TBL] [Abstract][Full Text] [Related]
27. Intratumor Heterogeneity in Breast Cancer. Beca F; Polyak K Adv Exp Med Biol; 2016; 882():169-89. PubMed ID: 26987535 [TBL] [Abstract][Full Text] [Related]
28. Thyroid Carcinoma: Phenotypic Features, Underlying Biology and Potential Relevance for Targeting Therapy. Hu J; Yuan IJ; Mirshahidi S; Simental A; Lee SC; Yuan X Int J Mol Sci; 2021 Feb; 22(4):. PubMed ID: 33669363 [TBL] [Abstract][Full Text] [Related]
29. Intratumor heterogeneity: evolution through space and time. Swanton C Cancer Res; 2012 Oct; 72(19):4875-82. PubMed ID: 23002210 [TBL] [Abstract][Full Text] [Related]
30. Intra-tumor heterogeneity from a cancer stem cell perspective. Prasetyanti PR; Medema JP Mol Cancer; 2017 Feb; 16(1):41. PubMed ID: 28209166 [TBL] [Abstract][Full Text] [Related]
33. Intratumor heterogeneity in human parathyroid tumors. Verdelli C; Tavanti GS; Corbetta S Histol Histopathol; 2020 Nov; 35(11):1213-1228. PubMed ID: 32468569 [TBL] [Abstract][Full Text] [Related]
34. Role of the Immune Component of Tumor Microenvironment in the Efficiency of Cancer Treatment: Perspectives for the Personalized Therapy. Stakheyeva M; Riabov V; Mitrofanova I; Litviakov N; Choynzonov E; Cherdyntseva N; Kzhyshkowska J Curr Pharm Des; 2017; 23(32):4807-4826. PubMed ID: 28714406 [TBL] [Abstract][Full Text] [Related]
35. Intratumor Heterogeneity and Antitumor Immunity Shape One Another Bidirectionally. Wolf Y; Samuels Y Clin Cancer Res; 2022 Jul; 28(14):2994-3001. PubMed ID: 35380639 [TBL] [Abstract][Full Text] [Related]
36. The microcosmos of intratumor heterogeneity: the space-time of cancer evolution. Janiszewska M Oncogene; 2020 Mar; 39(10):2031-2039. PubMed ID: 31784650 [TBL] [Abstract][Full Text] [Related]
37. Imaging intratumor heterogeneity: role in therapy response, resistance, and clinical outcome. O'Connor JP; Rose CJ; Waterton JC; Carano RA; Parker GJ; Jackson A Clin Cancer Res; 2015 Jan; 21(2):249-57. PubMed ID: 25421725 [TBL] [Abstract][Full Text] [Related]
38. Tumor Evolution, Heterogeneity, and Therapy for Our Patients With Advanced Cancer: How Far Have We Come? El-Deiry WS; Taylor B; Neal JW Am Soc Clin Oncol Educ Book; 2017; 37():e8-e15. PubMed ID: 28746017 [TBL] [Abstract][Full Text] [Related]
39. Intratumor heterogeneity index of breast carcinomas based on DNA methylation profiles. Campoy EM; Branham MT; Mayorga LS; Roqué M BMC Cancer; 2019 Apr; 19(1):328. PubMed ID: 30953488 [TBL] [Abstract][Full Text] [Related]
40. Engineering chimeric antigen receptor-T cells for cancer treatment. Ye B; Stary CM; Li X; Gao Q; Kang C; Xiong X Mol Cancer; 2018 Feb; 17(1):32. PubMed ID: 29448937 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]